1. Review the pathophysiology of uterine carcinosarcoma
  2. Identify the unique needs of the patients affected by uterine carcinosarcoma
  3. Review current strategies for treating uterine carcinosarcoma and discuss potential future directions


  1. Understand biologics’ role in escalating health care expenditures in the U.S.
  2. Compare and contrast the features of the small molecule-generic and biologic-biosimilar relationships and relevant regulation

3.   Evaluate barriers to biosimilar market penetration and individual prescribing

Session date: 
03/25/2019 - 12:00pm to 1:00pm CDT
5841 South Maryland Avenue
MC2115 HemOnc Conference Room E215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Meghan R. Steiner, MD and Garth W. Strohbehn, MD, MPhil